JP Morgan Chase’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-487,584
| Closed | -$261K | – | 7891 |
|
|
2024
Q4 | $261K | Buy |
487,584
+354,393
| +266% | +$247K | ﹤0.01% | 5365 |
|
|
2024
Q3 | $234K | Buy |
133,191
+126,752
| +1,969% | +$177K | ﹤0.01% | 5333 |
|
|
2024
Q2 | $7.53K | Sell |
6,439
-27,195
| -81% | -$68K | ﹤0.01% | 6312 |
|
|
2024
Q1 | $304K | Sell |
33,634
-10,399
| -24% | -$101K | ﹤0.01% | 5096 |
|
|
2023
Q4 | $479K | Buy |
44,033
+82
| +0.2% | +$615 | ﹤0.01% | 4826 |
|
|
2023
Q3 | $354K | Buy |
43,951
+3,667
| +9% | +$30.5K | ﹤0.01% | 4694 |
|
|
2023
Q2 | $437K | Buy |
40,284
+39,536
| +5,286% | +$339K | ﹤0.01% | 4569 |
|
|
2023
Q1 | $5K | Buy |
748
+128
| +21% | +$803 | ﹤0.01% | 6263 |
|
|
2022
Q4 | $2K | Sell |
620
-1,940
| -76% | -$9.54K | ﹤0.01% | 6357 |
|
|
2022
Q3 | $17K | Buy |
2,560
+490
| +24% | +$3.02K | ﹤0.01% | 5855 |
|
|
2022
Q2 | $10K | Sell |
2,070
-290,790
| -99% | -$1.77M | ﹤0.01% | 6040 |
|
|
2022
Q1 | $2.74M | Sell |
292,860
-5,261
| -2% | -$52.3K | ﹤0.01% | 3504 |
|
|
2021
Q4 | $3.54M | Sell |
298,121
-13,804
| -4% | -$159K | ﹤0.01% | 3348 |
|
|
2021
Q3 | $3.55M | Buy |
311,925
+180,939
| +138% | +$2.49M | ﹤0.01% | 3326 |
|
|
2021
Q2 | $2.35M | Sell |
130,986
-59,107
| -31% | -$951K | ﹤0.01% | 3681 |
|
|
2021
Q1 | $2.94M | Buy |
190,093
+27,834
| +17% | +$403K | ﹤0.01% | 3413 |
|
|
2020
Q4 | $1.98M | Sell |
162,259
-35,126
| -18% | -$490K | ﹤0.01% | 3485 |
|
|
2020
Q3 | $2.29M | Sell |
197,385
-106,277
| -35% | -$917K | ﹤0.01% | 3137 |
|
|
2020
Q2 | $3.08M | Sell |
303,662
-66,435
| -18% | -$611K | ﹤0.01% | 2815 |
|
|
2020
Q1 | $3.01M | Buy |
370,097
+245,717
| +198% | +$2.13M | ﹤0.01% | 2658 |
|
|
2019
Q4 | $1.07M | Buy |
124,380
+120,267
| +2,924% | +$675K | ﹤0.01% | 3802 |
|
|
2019
Q3 | $25K | Buy |
4,113
+667
| +19% | +$5.39K | ﹤0.01% | 5358 |
|
|
2019
Q2 | $54K | Buy |
3,446
+580
| +20% | +$10.1K | ﹤0.01% | 5140 |
|
|
2019
Q1 | $48K | Sell |
2,866
-6,549
| -70% | -$94.3K | ﹤0.01% | 5154 |
|
|
2018
Q4 | $108K | Sell |
9,415
-19,358
| -67% | -$392K | ﹤0.01% | 4824 |
|
|
2018
Q3 | $1.15M | Buy |
28,773
+2,222
| +8% | +$63.2K | ﹤0.01% | 3822 |
|
|
2018
Q2 | $751K | Buy |
26,551
+2,122
| +9% | +$47K | ﹤0.01% | 3980 |
|
|
2018
Q1 | $373K | Buy |
+24,429
| New | +$582K | ﹤0.01% | 4135 |
|
|
2016
Q2 | – | Sell |
-2,375
| Closed | -$51K | – | 5009 |
|
|
2016
Q1 | $51K | Buy |
+2,375
| New | +$50.3K | ﹤0.01% | 3898 |
|
JP Morgan Chase's MRNS Position: Q1 2025 in Review
JP Morgan Chase sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 487,584 shares — an estimated $261K sold.
JP Morgan Chase first reported a position in MRNS in Q1 2016 and held it in 29 quarters. The position peaked at $3.55M in Q3 2021. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- JP Morgan Chase reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- JP Morgan Chase sold 487,584 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $261K.
- JP Morgan Chase first reported a position in Marinus Pharmaceuticals, Inc in Q1 2016 and held it in 29 quarters.
- JP Morgan Chase's Marinus Pharmaceuticals, Inc position peaked at $3.55M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.